Antipyrine Benzocaine UPolycosanol 410 Brand Names
Auralgan | Otic Care | Treagan
What is Antipyrine Benzocaine UPolycosanol 410 combination medicine
Antipyrine Benzocaine UPolycosanol 410 are used together in an otic preparation to relieve pain and reduce inflammation associated with otitis media.
The combination is also used to facilitate ear wax removal. The original Auralgan formulation contained antipyrine and benzocaine.
Because it was available prior to 1938, it was considered a ‘grandfathered’ drug and was never officially FDA-approved.
A reformulated Auralgan otic solution contained acetic acid, antipyrine, benzocaine, and u-polycosanol 410 and also did not undergo the FDA approval process.
In March 2010, the FDA approved a formulation of Auralgan that contains the active ingredients Antipyrine Benzocaine UPolycosanol 410.
- cerumen removal
- otitis media
For the treatment of acute otitis media as adjuvant therapy to systemic antibiotics and for the reduction of pain and inflammation caused by the infection
No adverse reactions are regularly associated with the otic use of Antipyrine Benzocaine UPolycosanol 410.
Discontinue treatment if signs and symptoms (e.g., burning, pruritus, redness, or oozing sores in ear) of a local allergic reaction occur.
- laboratory monitoring not necessary
- ester local anesthetic hypersensitivity
- tympanic membrane perforation
There are no drug interactions associated with Antipyrine Benzocaine UPolycosanol 410.